Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:16:50.375Z.
Calculation as of: 2026-10-06T19:16:50.375Z.
Quote observation: 2026-10-06T19:13:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9cd3ead22764b77a02cf3e742533c366d0c9255af04c84535b20f2b2666bee2a
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gain Therapeutics, Inc. (GANX) | $71.66M | N/A | N/A | N/A | N/A |
| MindWalk Holdings Corp. (HYFT)vs › | $71.89M | N/A | N/A | N/A | N/A |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $72.09M | N/A | N/A | N/A | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $69.88M | N/A | 26.91 | 41.68 | 277.63 |
| Spero Therapeutics, Inc. (SPRO)vs › | $69.19M | 10.86 | 12.57 | 15.78 | 15.78 |
| Tiziana Life Sciences Ltd (TLSA)vs › | $68.72M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIO)vs › | $68.60M | 0.77 | 0.94 | 0.94 | 0.94 |
| Hyperfine, Inc. (HYPR)vs › | $75.41M | N/A | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $75.50M | N/A | N/A | N/A | N/A |
| Pulmonx Corporation (LUNG)vs › | $75.82M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.68
Forward EPS (Est.)
$-0.50
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
